Carr Patricia's Form 4 filing
Jazz Pharmaceuticals plc (JAZZ) · filed Mar 9, 2026
- Accession no.
- 0001784606-26-000012
- Filed
- Mar 9, 2026
- Trade date
- Mar 5-9, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $235.4K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Carr PatriciaCIK 0001784606 | Officer (SVP, Chief Accounting Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | Ordinary Shares | FTax withholdingDisposed | −1,436 | $186.77F2 | −$268,201.72 | 7,799 | Direct | |
| Mar 9, 2026 | Ordinary Shares | SSaleDisposed | −1,287 | $182.94 | −$235,443.78 | 6,512 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $186.06 to $186.9115. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Referenced by the price of 1 transaction in Table I.